Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.11
-1.3%
$20.13
$11.50
▼
$22.13
$7.40B1.244.08 million shs1.67 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$129.36
-4.7%
$163.75
$123.00
▼
$260.19
$6.80B0.861.15 million shs811,749 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$63.56
-2.2%
$99.03
$28.66
▼
$126.38
$7.58B0.541.34 million shs1.09 million shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$49.55
-7.2%
$54.88
$26.00
▼
$72.64
$2.64B0.17531,052 shs581,888 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-1.16%-1.24%+4.52%+17.89%+83.28%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-4.66%-8.70%-17.24%-37.74%-11.86%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-2.18%-12.86%-45.34%-48.01%-16.47%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-7.23%-11.42%-8.12%-25.30%+80.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.11
-1.3%
$20.13
$11.50
▼
$22.13
$7.40B1.244.08 million shs1.67 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$129.36
-4.7%
$163.75
$123.00
▼
$260.19
$6.80B0.861.15 million shs811,749 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$63.56
-2.2%
$99.03
$28.66
▼
$126.38
$7.58B0.541.34 million shs1.09 million shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$49.55
-7.2%
$54.88
$26.00
▼
$72.64
$2.64B0.17531,052 shs581,888 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-1.16%-1.24%+4.52%+17.89%+83.28%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-4.66%-8.70%-17.24%-37.74%-11.86%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-2.18%-12.86%-45.34%-48.01%-16.47%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-7.23%-11.42%-8.12%-25.30%+80.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.80
Moderate Buy$23.008.93% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.86
Moderate Buy$266.21105.79% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.63
Moderate Buy$139.50119.47% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.79
Moderate Buy$87.3076.19% Upside

Current Analyst Ratings Breakdown

Latest MBX, CORT, AXSM, and AMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
UpgradeHold (C+) ➝ Buy (B-)
11/13/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetEqual Weight$249.00 ➝ $223.00
11/12/2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Initiated CoverageBuy$90.00
11/10/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C+)
11/5/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOutperform$23.00 ➝ $25.00
11/4/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
UpgradeHold (C) ➝ Hold (C+)
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingOverweight$21.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOverweight$24.00 ➝ $25.00
11/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetOutperform$284.00 ➝ $272.00
11/4/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Reiterated RatingOverweight$165.00 ➝ $173.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingOutperform
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.02B2.44$1.55 per share13.60$1.52 per share13.89
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$865.27M7.86N/AN/A$2.00 per share64.68
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$761.41M9.14$0.83 per share76.68$7.62 per share8.34
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/A$9.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4250.2718.682.424.17%283.50%7.79%N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.06N/A35.34N/A-18.18%-198.73%-22.03%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$1.2750.0517.46N/A16.53%22.56%17.83%N/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-$86.97M-$3.07N/AN/AN/AN/A-34.37%-32.72%N/A

Latest MBX, CORT, AXSM, and AMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-$0.80-$1.29-$0.49-$1.29N/AN/A
11/3/2026Q3 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.23$0.26+$0.03-$0.06N/A$862.68 million
11/3/2026Q3 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.84$1.01+$0.17$1.01$339.13 million$340.47 million
11/2/2026Q3 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.6343-$0.25+$0.3843-$0.25$249.19 million$259.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
5.61
1.87
1.24
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.21
1.42
1.34
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.00
2.94
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
19.58
19.58

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
31.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500348.41 million288.14 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
92552.60 million41.76 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
730109.44 million86.79 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
6349.66 million34.22 millionOptionable

Recent News About These Companies

MBX Biosciences (MBX) Stock Looks Above Fair Value On Phase 3 Progress
Brokers Issue Forecasts for MBX Biosciences FY2026 Earnings
HC Wainwright Forecasts MBX Biosciences FY2026 Earnings
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
MBX Biosciences (NASDAQ:MBX) CEO Sells 4,893 Shares of Stock
MBX Biosciences (NASDAQ:MBX) Now Covered by HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$21.11 -0.28 (-1.29%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$21.45 +0.34 (+1.59%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$129.36 -6.32 (-4.66%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$127.98 -1.39 (-1.07%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$63.56 -1.42 (-2.18%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$63.01 -0.55 (-0.87%)
As of 11/20/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

MBX Biosciences stock logo

MBX Biosciences NASDAQ:MBX

$49.55 -3.86 (-7.23%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$48.19 -1.36 (-2.75%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include: • MBX 2109: Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the concentration of active drug observed immediately prior to the next dose, or peak-to-trough ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and dosed our first patient in this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. • MBX 1416: We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide-1, or GLP-1, receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase 1 clinical trial, preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. • Obesity portfolio: Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptor co-agonist prodrug with the goal of reducing dosing frequency and improving efficacy and tolerability relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly GLP-1/GIP co-agonist, and an extended duration of action of the active component of MBX 4291, supporting the potential for once-monthly administration. During our preclinical studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in IND-enabling studies with an anticipated investigational new drug, or IND, submission in the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the lead optimization stage of development. Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic peptides often have significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours by the liver and kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target selectivity, 3) half-lives that allow for dosing at weekly or less frequent intervals, and 4) low or flat peak-to-trough ratios to improve tolerability, thereby facilitating higher dosing and greater potential efficacy. We were founded as MBX Biosciences LLC, an Indiana limited liability company, in August 2018. We converted to a Delaware corporation in April 2019 and incorporated under the name MBX Biosciences, Inc. Our principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana.